309 related articles for article (PubMed ID: 31981686)
1. International landscape of limits and recommendations for occupational exposure to engineered nanomaterials.
Rodríguez-Ibarra C; Déciga-Alcaraz A; Ispanixtlahuatl-Meráz O; Medina-Reyes EI; Delgado-Buenrostro NL; Chirino YI
Toxicol Lett; 2020 Apr; 322():111-119. PubMed ID: 31981686
[TBL] [Abstract][Full Text] [Related]
2. Workshop report: strategies for setting occupational exposure limits for engineered nanomaterials.
Gordon SC; Butala JH; Carter JM; Elder A; Gordon T; Gray G; Sayre PG; Schulte PA; Tsai CS; West J
Regul Toxicol Pharmacol; 2014 Apr; 68(3):305-11. PubMed ID: 24462629
[TBL] [Abstract][Full Text] [Related]
3. Harmonization efforts for deriving health-based exposure limits in the pharmaceutical industry - Advancing the current science and practice.
Weideman PA; Pecquet AM; Maier MA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S1-2. PubMed ID: 27531049
[No Abstract] [Full Text] [Related]
4. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology.
Oberdörster G
J Intern Med; 2010 Jan; 267(1):89-105. PubMed ID: 20059646
[TBL] [Abstract][Full Text] [Related]
5. Characterizing risk assessments for the development of occupational exposure limits for engineered nanomaterials.
Schulte PA; Kuempel ED; Drew NM
Regul Toxicol Pharmacol; 2018 Jun; 95():207-219. PubMed ID: 29574195
[TBL] [Abstract][Full Text] [Related]
6. Using default methodologies to derive an acceptable daily exposure (ADE).
Faria EC; Bercu JP; Dolan DG; Morinello EJ; Pecquet AM; Seaman C; Sehner C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S28-38. PubMed ID: 27233926
[TBL] [Abstract][Full Text] [Related]
7. A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.
Hayes EP; Jolly RA; Faria EC; Barle EL; Bercu JP; Molnar LR; Naumann BD; Olson MJ; Pecquet AM; Sandhu R; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S39-47. PubMed ID: 27267172
[TBL] [Abstract][Full Text] [Related]
8. Towards health-based nano reference values (HNRVs) for occupational exposure: Recommendations from an expert panel.
Visser M; Gosens I; Bard D; van Broekhuizen P; Janer G; Kuempel E; Riediker M; Vogel U; Dekkers S
NanoImpact; 2022 Apr; 26():100396. PubMed ID: 35560294
[TBL] [Abstract][Full Text] [Related]
9. Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.
Gould J; Callis CM; Dolan DG; Stanard B; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S79-93. PubMed ID: 27233924
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Human Exposure to ENMs.
Jiménez AS; van Tongeren M
Adv Exp Med Biol; 2017; 947():27-40. PubMed ID: 28168664
[TBL] [Abstract][Full Text] [Related]
11. Characterizing workforces exposed to current and emerging non-carbonaceous nanomaterials in the U.S.
Babik KR; Dahm MM; Dunn KH; Dunn KL; Schubauer-Berigan MK
J Occup Environ Hyg; 2018 Jan; 15(1):44-56. PubMed ID: 29053929
[TBL] [Abstract][Full Text] [Related]
12. Identifying and assessing highly hazardous drugs within quality risk management programs.
Sussman RG; Schatz AR; Kimmel TA; Ader A; Naumann BD; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S11-8. PubMed ID: 27267171
[TBL] [Abstract][Full Text] [Related]
13. In silico analysis of nanomaterials hazard and risk.
Cohen Y; Rallo R; Liu R; Liu HH
Acc Chem Res; 2013 Mar; 46(3):802-12. PubMed ID: 23138971
[TBL] [Abstract][Full Text] [Related]
14. A harmonization effort for acceptable daily exposure derivation - Considerations for application of adjustment factors.
Sussman RG; Naumann BD; Pfister T; Sehner C; Seaman C; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S57-66. PubMed ID: 27221789
[TBL] [Abstract][Full Text] [Related]
15. Health and safety implications of occupational exposure to engineered nanomaterials.
Stebounova LV; Morgan H; Grassian VH; Brenner S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2012; 4(3):310-21. PubMed ID: 22131295
[TBL] [Abstract][Full Text] [Related]
16. Literature Review of (Q)SAR Modelling of Nanomaterial Toxicity.
Oksel C; Ma CY; Liu JJ; Wilkins T; Wang XZ
Adv Exp Med Biol; 2017; 947():103-142. PubMed ID: 28168667
[TBL] [Abstract][Full Text] [Related]
17. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
Reichard JF; Maier MA; Naumann BD; Pecquet AM; Pfister T; Sandhu R; Sargent EV; Streeter AJ; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S67-78. PubMed ID: 27224509
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment and risk management of nanomaterials in the workplace: translating research to practice.
Kuempel ED; Geraci CL; Schulte PA
Ann Occup Hyg; 2012 Jul; 56(5):491-505. PubMed ID: 22752094
[TBL] [Abstract][Full Text] [Related]
19. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
[TBL] [Abstract][Full Text] [Related]
20. Issues and approaches for ensuring effective communication on acceptable daily exposure (ADE) values applied to pharmaceutical cleaning.
Olson MJ; Faria EC; Hayes EP; Jolly RA; Barle EL; Molnar LR; Naumann BD; Pecquet AM; Shipp BK; Sussman RG; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S19-27. PubMed ID: 27233923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
